U.S. Markets closed

La Jolla Pharmaceutical (LJPC) Surges: Stock Moves 11.1% Higher

Zacks Equity Research

La Jolla Pharmaceutical Company LJPC was a big mover last session, as the company saw its shares rise over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $23.91 –$33.35 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen two negative estimate revisions in the past two months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

La Jolla Pharmaceutical currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

La Jolla Pharmaceutical Company Price and Consensus

La Jolla Pharmaceutical Company Price and Consensus | La Jolla Pharmaceutical Company Quote

A better-ranked stock in the Medical - Drugs industry is Sucampo Pharmaceuticals, Inc. SCMP, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is LJPC going up? Or down? Predict to see what others think: Up or Down

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Sucampo Pharmaceuticals, Inc. (SCMP) : Free Stock Analysis Report
 
La Jolla Pharmaceutical Company (LJPC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research